Get the Stockscreener App
2.82
3.41%
-0.11
Fortress Biotech Inc stock is traded at $2.82, with a volume of 672.88K.
It is down -3.41% in the last 24 hours and down -15.77% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See More
Previous Close:
$2.93
Open:
$2.89
24h Volume:
672.88K
Relative Volume:
1.11
Market Cap:
$93.38M
Revenue:
$66.16M
Net Income/Loss:
$128.94M
P/E Ratio:
0.8862
EPS:
3.1823
Net Cash Flow:
$152.08M
1W Performance:
+2.91%
1M Performance:
-15.77%
6M Performance:
-19.14%
1Y Performance:
+33.49%
1-Day Range:
$2.7301
$2.8962
1-Week Range:
$2.57
$3.055
52-Week Range:
$1.9907
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.80 | 97.72M | 66.16M | 128.94M | 152.08M | 3.1823 |
VRTX
Vertex Pharmaceuticals Inc
|
516.25 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.82 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.77 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.15 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.23 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Fortress Biotech earnings beat by $0.11, revenue fell short of estimates - Investing.com Canada
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Fortress Biotech: Q2 Earnings Snapshot - marketscreener.com
Fortress Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary - TradingView
Fortress Biotech (NASDAQ: FBIO) gains $158.9M from voucher sale and boosts cash - Stock Titan
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Q2 Earnings Call Highlights - MarketBeat
FBIO Looks 125.0% Overvalued on GF Value™ Ahead of Q2 Earnings - GuruFocus
Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fortress Biotech Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
The Technical Signals Behind (FBIOP) That Institutions Follow - Stock Traders Daily
Law firm investigates Fortress Biotech for poss... - Pluang
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after market close on August 12. - 富途牛牛
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO) - PR Newswire
Fortress Biotech (FBIO) to Release Earnings on Thursday - MarketBeat
Best Cheap Stocks Under $10 with High Return Potential (August 2026) - Investing.com
Fortress Biotech Just Netted $159 MillionIts Preferred Shares Could Be The Real Winner - Seeking Alpha
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing - marketscreener.com
Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fortress Biotech Inc (FBIO) Balance Sheet - TradingKey
Fortress Biotech Inc (FBIO) Institutional Confidence - TradingKey
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing - The Manila Times
FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090 - TradingKey
Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Journey Medical Corp (DERM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Income Statement - TradingKey
Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy - Seeking Alpha
Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume TradingMerger Arbitrage - dars.gov.et
Technical Reactions to FBIOP Trends in Macro Strategies - Stock Traders Daily
$3.74 | Fortress Biotech, Inc. Common Stock (FBIO) Stock Price Today - Binance
Fortress Biotech Achieves 73.6% Return in the Stock Market Over Past Year - MarketsMojo
MSN Money - MSN
CNB0 Bond Coupon Profile — Rate & Payments - TradingView
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion - BioBuzz
Fortress Biotech Preferred Stock (FBIOP) Edges Lower as Support Levels Are TestedChaikin Flow - dars.gov.et
Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesEarnings Weakness Phase - dars.gov.et
Fortress Biotech (FBIO) Edges Lower Amid Quiet Trading, Holds Above Key SupportWeekly Profile - DonanımHaber
Fortress Biotech highlights its biotech portfolio strategy as a Nasdaq-listed micro-cap - Ad Hoc News
Mustang Bio (MBIO) Proxy Filing Summary - Quartr
Mustang Bio (MBIO) Registration Filing Summary - Quartr
Fortress Biotech Preferred Shares (FBIOP) Slide 1.98% as Support Test ApproachesPut Flow Alert - dars.gov.et
Fortress Biotech focuses on specialty pharma growth and licensing model - Ad Hoc News
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 B - GuruFocus
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):